Booming Moderna is raising $600M while ramping up manufacturing and clinical studies
Ever since Flagship launched Moderna back in 2012 with a $40 million round, the biotech has been a perpetual money-raising machine, garnering well over a billion dollars from an avid group of investors and partners looking to participate in its promised drug R&D revolution. And now in a filing with the SEC, the company has outlined its latest big effort to add $600 million to its coffers, with most of the cash already in hand.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.